Sientra (NASDAQ:SIEN)‘s stock had its “buy” rating reiterated by analysts at Canaccord Genuity in a report issued on Friday. They presently have a $19.00 price target on the medical instruments supplier’s stock. Canaccord Genuity’s price target would indicate a potential upside of 38.18% from the company’s current price.

A number of other research firms have also weighed in on SIEN. BidaskClub lowered Sientra from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. ValuEngine upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. William Blair upgraded Sientra from a “market perform” rating to an “outperform” rating in a research note on Wednesday, September 13th. Stifel Nicolaus restated a “hold” rating and set a $14.00 price target (up previously from $11.00) on shares of Sientra in a research note on Wednesday, September 27th. Finally, Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Tuesday. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $15.00.

Sientra (NASDAQ SIEN) traded down $0.28 during midday trading on Friday, hitting $13.75. 84,000 shares of the stock traded hands, compared to its average volume of 90,667. Sientra has a 12-month low of $7.20 and a 12-month high of $16.68. The stock has a market cap of $266.69, a price-to-earnings ratio of -4.82 and a beta of -1.47. The company has a quick ratio of 1.92, a current ratio of 2.87 and a debt-to-equity ratio of 0.57.

Sientra (NASDAQ:SIEN) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.06). Sientra had a negative net margin of 169.77% and a negative return on equity of 68.82%. The business had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $10.54 million. During the same period in the previous year, the company earned ($0.55) EPS. Sientra’s revenue for the quarter was up 50.8% compared to the same quarter last year. analysts forecast that Sientra will post -3.23 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Bamco Inc. NY raised its position in Sientra by 109.3% during the second quarter. Bamco Inc. NY now owns 471,500 shares of the medical instruments supplier’s stock valued at $4,583,000 after acquiring an additional 246,183 shares in the last quarter. EAM Investors LLC acquired a new position in shares of Sientra in the 3rd quarter valued at $3,018,000. Pura Vida Investments LLC acquired a new position in shares of Sientra in the 3rd quarter valued at $2,892,000. State Street Corp acquired a new position in shares of Sientra in the 2nd quarter valued at $1,449,000. Finally, Northern Trust Corp raised its holdings in shares of Sientra by 449.4% in the 2nd quarter. Northern Trust Corp now owns 149,227 shares of the medical instruments supplier’s stock valued at $1,451,000 after buying an additional 122,066 shares during the period. Hedge funds and other institutional investors own 76.63% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Sientra (SIEN) Earns Buy Rating from Canaccord Genuity” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/05/sientra-sien-earns-buy-rating-from-canaccord-genuity.html.

About Sientra

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.